News

The purchase price of Dava is $575m in cash, with additional consideration of about $25m contingent on the achievement of certain sales milestones. The acquisition would improve Endo’s

The company said that the patent has broad coverage and protects development of any apoptosis-inducing ICAM-1 antibody. BioInvent chief scientific officer Björn Frendéus said the company is happy

Bristol-Myers Squibb will expand access to a broader set of clinical trial information from in-scope company-sponsored studies and enable an independent scientific review through DCRI of requests from

In June 2014, EnGeneIC completed a Phase 1 trial in recurrent glioma in Australia and now plans to submit an IND and commence the U.S. clinical program in

Bruce Burns, Senior Vice President at Windmill, said, "Our pharmacies like the fact that we bring them new innovative products of this caliber." "We have nothing else like

This first step towards identification of new classes of targeted anti-infectious drugs was achieved only 9 months after signature of a discovery collaboration will trigger the payment of

Preliminary data from the Cook/Selexis-sponsored proof-of-concept program has been published in the June issue of BioProcess International in an article titled, "Rapid Development and Scale-Up Through Strategic Partnership:

As part of the option deal, Aurigene will receive an upfront payment from Orion, followed by a licensing fee, milestones and royalties upon exercising the option at the

According to the company, early launch of these products was fueled by the strong feedback from many national retailers in the US. The company has been working with